Polyoxazoline: Chemistry, Properties, and Applications in Drug DeliveryTacey X. Viegas, Francesco M. Veronese, Michael D. Bentley et al.|Bioconjugate Chemistry|2011Cited by 424
Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson’s disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indicationsRandall W. Moreadith, Warren Olanow, Bekir Dizman et al.|European Polymer Journal|2016Cited by 175
Selective conjugation of poly(2-ethyl 2-oxazoline) to granulocyte colony stimulating factorAnna Mero, Tacey X. Viegas, Zhihao Fang et al.|Journal of Controlled Release|2012Cited by 80
Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefitKaren L. Eskow Jaunarajs, Randall W. Moreadith, David G. Standaert et al.|Movement Disorders|2013Cited by 68
Tuning drug release from polyoxazoline-drug conjugatesJ. Milton Harris, Lars Nordstierna, Michael D. Bentley et al.|European Polymer Journal|2019Cited by 50